Thursday, 06 August 2020


New migraine study reveals Alder drug’s treatment benefits

25 April 2018 | News

The data are being presented at the American Academy of Neurology Annual Meeting in Los Angeles.

 Singapore – Results from a Phase 3 clinical trial, PROMISE 1, assessing Alder BioPharmaceuticals' long-acting eptinezumab for the prevention of migraine showed a significant treatment effect. The data are being presented at the American Academy of Neurology Annual Meeting in Los Angeles.

For months six through 12 (quarterly doses three and four), 70.7% of patients achieved an average 50% or greater reduction of migraine days from baseline compared to 58.7% for placebo. The results represented an 8.9% improvement from the reductions observed during the first and second quarterly doses.

The company plans to file a U.S. marketing application later this year.

Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein involved in the transmission of, and heightened sensitivity to, migraine-related pain. It is administered via infusion once every three months.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls